PHARM Pharming Group N.V.
Price Chart
Executive Summary
Pharming announced multiple presentations at the 2026 CIS Annual Meeting, including interim data from a long-term extension study of leniolisib in pediatric APDS patients aged 4-11 and clinical experience data in CVID/CVID-like disorders. The presentations support ongoing Phase II trials in broader primary immunodeficiencies, with results expected in H2 2026. This is a routine scientific update with no material financial data or regulatory catalyst.
Actionable Insight
Monitor Phase II trial results in H2 2026 for potential label expansion into CVID and broader PIDs, which could expand leniolisib's addressable market. No immediate trading catalyst from this scientific conference update.
Key Facts
- Presentations at CIS 2026 include interim safety/efficacy data from leniolisib long-term extension study in pediatric APDS patients aged 4-11
- Clinical experience data on leniolisib for immune dysregulation in CVID and CVID-like disorders presented
- Two Phase II trials (NCT06897358, NCT06549114) evaluating leniolisib in CVID and PIDs with immune dysregulation are underway
- Results from ongoing Phase II trials expected in second half of 2026
- Leniolisib is already approved for APDS in US, UK, Australia, Israel (ages 12+) and Japan (ages 4+)
- No financial data, revenue, EPS, or guidance provided in the press release
Financial Impact
No financial figures disclosed; impact is limited to potential pipeline expansion signal
Risk Factors
- Phase II trials may fail to meet endpoints, limiting label expansion
- Regulatory reviews in Canada and other countries may be delayed or negative
- Competition from other PI3Kδ inhibitors or alternative therapies
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289580 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
15d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
May 7, 2026
5w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
May 7, 2026
5w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 23, 2026
7w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 7, 2026
9w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 2, 2026
10w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 27, 2026
11w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 24, 2026
11w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 12, 2026
13w ago
|
Press Release
| — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access